| Net sales from continuing operations | 50,317a | 45,440a | 42,206a |
| Other revenues | 1,405a | 1,220a | 1,255a |
| Cost of goods sold | -12,827a | -12,472a | -11,582a |
| Gross profit from continuing operations | 38,895a | 34,188a | 31,879a |
| Selling, general and administration | -12,566a | -12,517a | -12,193a |
| Research and development | -10,022a | -11,371a | -9,172a |
| Other income | 1,175a | 1,772a | 696a |
| Other expense | -2,938a | -2,303a | -3,264a |
| Operating income from continuing operations | 14,544a | 9,769a | 7,946a |
| Loss from associated companies | -38a | -13a | -11a |
| Interest expense | -1,006a | -855a | -800a |
| Other financial income and expense | 140a | 222a | 42a |
| Income before taxes from continuing operations | 13,640a | 9,123a | 7,177a |
| Income taxes | -1,701a | -551a | -1,128a |
| Net income from continuing operations | 11,939a | 8,572a | 6,049a |
| Net income from discontinued operations before gain on distribution of Sandoz Group AG to Novartis AG shareholders | 0a | 422a | 906a |
| Gain on distribution of Sandoz Group AG to Novartis AG shareholders | 0a | 5,860a | 0a |
| Net income from discontinued operations | 0a | 6,282a | 906a |
| Net income | 11,939a | 14,854a | 6,955a |
| Attributable to | — | — | — |
| Shareholders of Novartis AG | 11,941a | 14,850a | 6,955a |
| Non-controlling interests | -2a | 4a | 0a |